Trial Profile

Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma With MGMT Methylated or Unmethylated Promoter Status

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium 68 NeoBOMB1 (Primary) ; Lutetium-177 NeoBOMB1 (Primary) ; Temozolomide
Indications Glioblastoma
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

21 Oct 2025 Planned End Date changed from 28 Aug 2031 to 1 Jul 2032.
21 Oct 2025 Planned primary completion date changed from 5 Feb 2026 to 10 Dec 2026.
21 Oct 2024 Planned End Date changed from 1 Jun 2026 to 28 Aug 2031.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com